(Q34950289)

5 August 2017

1 reference

title

A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health (English)

1 reference

5 August 2017

1 reference

Michael S Ewer

1

1 reference

5 August 2017

Stefan Glück

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

115

1 reference

5 August 2017

issue

9

1 reference

5 August 2017

page(s)

1813-1826

1 reference

Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Early breast cancer therapy and cardiovascular injury.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Meta-analysis of vascular and neoplastic events associated with tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Cardiovascular trials of estrogen replacement therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Decreased risk of stroke among 10-year survivors of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Weight, weight gain, and survival after breast cancer diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Long term effects of tamoxifen on blood lipid values in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging dise

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Adiposity, adult weight change, and postmenopausal breast cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24219

7 January 2021

Identifiers

DOI

10.1002/CNCR.24219

1 reference

5 August 2017

1 reference